Nuveen LLC Takes $233,000 Position in Lineage Cell Therapeutics, Inc. $LCTX

Key Points

• Nuveen LLC acquired approximately $233,000 worth of shares in Lineage Cell Therapeutics, owning about 0.23% of the company as of its latest SEC filing.
• Several other institutional investors, including Two Sigma Advisers LP and Comerica Bank, also significantly increased their stakes in Lineage Cell Therapeutics during the fourth quarter, reflecting growing interest in the company.
• Analysts have issued buy ratings for Lineage Cell Therapeutics, with target prices ranging from $2.00 to $9.00, indicating optimism about future performance.

Nuveen LLC bought a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 515,445 shares of the company's stock, valued at approximately $233,000. Nuveen LLC owned about 0.23% of Lineage Cell Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Two Sigma Advisers LP increased its stake in shares of Lineage Cell Therapeutics by 312.2% during the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock worth $44,000 after acquiring an additional 65,864 shares during the period. Two Sigma Investments LP acquired a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth about $152,000. Barclays PLC increased its stake in shares of Lineage Cell Therapeutics by 10.8% during the fourth quarter. Barclays PLC now owns 234,069 shares of the company's stock worth $118,000 after acquiring an additional 22,769 shares during the period. Comerica Bank increased its stake in shares of Lineage Cell Therapeutics by 220.0% during the fourth quarter. Comerica Bank now owns 800,000 shares of the company's stock worth $402,000 after acquiring an additional 550,000 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth about $46,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Trading Up 1.7%

Shares of LCTX opened at $1.22 on Friday. The firm's 50-day moving average is $1.07 and its two-hundred day moving average is $0.75. Lineage Cell Therapeutics, Inc. has a twelve month low of $0.37 and a twelve month high of $1.31. The firm has a market capitalization of $278.60 million, a P/E ratio of -6.78 and a beta of 1.66.

Wall Street Analysts Forecast Growth

LCTX has been the subject of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Monday, June 23rd. D. Boral Capital reissued a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Wednesday, August 27th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics presently has a consensus rating of "Buy" and an average target price of $4.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.